A study found that structured exercise after adjuvant chemotherapy for high-risk Stage II/III colon cancer significantly improved disease-free and overall survival. The impact, with a hazard ratio of 0.6 for OS, is comparable to some approved drugs, making it a practice-changing and cost-effective intervention.

While both are crucial, if one must be prioritized, weight training is superior for healthy aging. It provides nearly all the same cardiovascular benefits as dedicated cardio, plus the unique and essential benefits of increasing lean muscle mass, strength, and bone density, which are critical for late-life functionality.

The clinical goal for prescribing exercise dictates the regimen. A prescription for managing treatment-related fatigue will differ significantly from one intended as a direct anti-cancer therapy or for preventing long-term cardiometabolic disease. The type, dose, and intensity must match the specific indication.

The CHALENSE study demonstrated that a structured exercise program after adjuvant chemotherapy improved disease-free and overall survival in colon cancer patients. The magnitude of this benefit is comparable to that of established chemotherapy drugs like oxaliplatin, making exercise a critical, non-pharmacological standard of care.

Current exercise guidelines suggest a 2:1 ratio of moderate-to-vigorous exercise based on calorie burn. However, new data shows the ratio is closer to 8:1 for reducing death from cardiovascular disease, highlighting the disproportionate value of intensity.

Generic advice like "diet and exercise" is ineffective for cancer patients. Clinicians should adopt a pharmaceutical model, prescribing specific types and "doses" of diet and exercise based on a patient's unique metabolic profile, treatment, and clinical goals, rather than handing out a generic brochure.

A study requiring participants to perform a grueling HIIT protocol (4 sets of 4 minutes at 85-95% max heart rate) three times a week resulted in significant improvements in hippocampal structure and function. Remarkably, these benefits were maintained for several years after the trial ended.

Data from the CO21 trial shows a structured exercise program provides a 7% improvement in overall survival for high-risk colon cancer patients. This non-pharmacological intervention demonstrates a greater survival benefit than the established 5% gain from adding oxaliplatin to chemotherapy.

Dr. Rhonda Patrick highlights research showing that three daily, three-minute bursts of intense, unstructured activity (like sprinting up stairs) dramatically reduces mortality risks from all causes, cancer, and cardiovascular disease.